SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Piramal Pharma - Quaterly Results

03 Aug 2023 Evaluate
The company witnessed a 13.39% growth in the revenue at Rs. 8464.30 millions for the quarter ended June 2023 as compared to Rs. 7464.70 millions during the year-ago period.The Net Loss for the quarter ended June 2023 is Rs. -333.60 millions as compared to Net Loss of Rs. -171.20 millions of corresponding quarter ended June 2022The company reported a good operating profit of 432.70 millions compared to 404.90 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202306 202206 % Var 202306 202206 % Var 202303 202203 % Var
Sales 8464.30 7464.70 13.39 8464.30 7464.70 13.39 34432.20 33404.20 3.08
Other Income 266.80 1066.10 -74.97 266.80 1066.10 -74.97 3410.70 2247.90 51.73
PBIDT 432.70 404.90 6.87 432.70 404.90 6.87 4386.00 7000.70 -37.35
Interest 338.00 203.10 66.42 338.00 203.10 66.42 1158.70 572.90 102.25
PBDT 94.70 201.80 -53.07 94.70 201.80 -53.07 3157.70 6277.00 -49.69
Depreciation 503.70 447.80 12.48 503.70 447.80 12.48 1920.80 1653.70 16.15
PBT -409.00 -246.00 66.26 -409.00 -246.00 66.26 1236.90 4623.30 -73.25
TAX -75.40 -74.80 0.80 -75.40 -74.80 0.80 541.90 947.90 -42.83
Deferred Tax -75.40 -74.80 0.80 -75.40 -74.80 0.80 154.20 -160.30 -196.19
PAT -333.60 -171.20 94.86 -333.60 -171.20 94.86 695.00 3675.40 -81.09
Equity 11933.20 11859.10 0.62 11933.20 11859.10 0.62 11933.20 11859.10 0.62
PBIDTM(%) 5.11 5.42 -5.75 5.11 5.42 -5.75 12.74 20.96 -39.22

Piramal Pharma Share Price

148.60 -0.30 (-0.20%)
20-Apr-2026 15:18 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1667.00
Dr. Reddys Lab 1230.30
Cipla 1228.30
Zydus Lifesciences 936.80
Lupin 2326.40
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×